EUCTR2013-003698-82-CZ进行中（未招募）1 期
A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of subjects with T2DM With Inadequate Glycemic Control on Metformin Monotherapy - MK-8835/PF-04971729 and Sitagliptin Co-administration Factorial Study
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At Visit 1/Screening
- •1. Have T2DM in accordance with ADA guidelines [15] and be =18 years of age on the day of signing the ICF.
- •2. Meet one of the following criteria:
- •* On metformin monotherapy (=1500 mg/day) for =8 weeks with a Visit 1/Screening A1C =7.5% and =11.0% (=58 mmol/mol and =97 mmol/mol)
- •* On metformin monotherapy (=1500 mg/day) for <8 weeks with a Visit 1/Screening A1C =7.5% and =11.0% (=58 mmol/mol and =97 mmol/mol)
- •* On metformin monotherapy <1500 mg/day with a Visit 1/Screening A1C =8.0%
- •and =11.5% (=64 mmol/mol and =102 mmol/mol)
- •3. Have a body mass index (BMI) =18.0 kg/m2.
- •4. Have personally signed and dated the ICF indicating that he/she has been informed of all pertinent aspects of the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
- •5. Be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •6. Meet one of the following criteria:
- •a. Subject is a male
- •b. Subject is a female not of reproductive potential defined as one who:
- •(1) is postmenopausal (defined as at least 12 months with no menses in women
- •=45 years of age) or
- •(2) has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal
- •ligation or occlusion at least 6 weeks prior to Visit 1/Screening
- •c. Subject is a female of reproductive potential and:
- •(1) agrees to remain abstinent from heterosexual activity† or
- •(2) agrees to use (or have their partner use) acceptable contraception to prevent
- •pregnancy within the projected duration of the trial and for 14 days after the last
- •dose of blinded investigational product. Two methods of contraception will be
- •used to avoid pregnancy. Acceptable combinations of methods include:
- •Use of one of the following double-barrier methods: diaphragm with spermicide and a condom; cervical cap and a condom; or a contraceptive sponge and condom.
- •Use of hormonal contraception (any registered and marketed contraceptive
- •agent that contains an estrogen and/or a progestational agent [including oral,
- •subcutaneous, intrauterine and intramuscular agents, and cutaneous patch]) with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; vasectomy; or IUD.
- •Use of an IUD with one of the following: condom; diaphragm with spermicide; contraceptive sponge; vasectomy; or hormonal contraception (see above).
- •Vasectomy with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; IUD; or hormonal contraception (see above).
- •† Abstinence can be used as the sole method of contraception if it is in line with the subject’s preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
- •At Visit 3/Week -2
- •7. Be on metformin monotherapy (=1500 mg/day) for =8 weeks with a Visit 3/Week -2 A1C =7.5% and =11.0% (=58 mmol/mol and =97 mmol/mol).
- •Note: Subjects who are already on metformin at =1500 mg/day for =8 weeks at Visit 1/Screening, going directly to a combined Visit 2/3 at Week -2, will have the
- •Visit 1/Screening A1C determination used to assess this inclusion criterion if the
- •Visit 1/Screening A1C was obtained within 2 weeks of the combined V
排除标准
- •At Visit 1/Screening
- •Diabetes Diagnosis and Prior Therapy Criteria
- •1. Has a history of type 1 diabetes mellitus or a history of ketoacidosis or subject assessed by the investigator as possibly having type 1 diabetes mellitus confirmed
- •with a C-peptide <0.7 ng/mL (0.23 nmol/L).
- •Note: Only subjects assessed by the investigator as possibly having type 1 diabetes
- •should have C-peptide measured at Visit 1/Screening.
- •2. Has a history of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).
- •3. Has a known hypersensitivity or intolerance to any SGLT2 inhibitor or sitagliptin.
- •4. Has been treated with any of the following agents within 12 weeks of Visit
- •1/Screening or during the pre-randomization period:
- •* Insulin of any type (except for short-term use [i.e., =7 days] during concomitant
- •illness or other stress)
- •* Other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide,
- •liraglutide)
- •* Pioglitazone or rosiglitazone
- •* Other SGLT2 inhibitors
- •* Alpha glucosidase inhibitors or meglitinides
- •* Dipeptidyl-peptidase 4 inhibitor (DPP-4 inhibitor)
- •* Sulfonylureas (SUs)
- •* Bromocriptine (Cycloset™)
- •* Colesevelam (Welchol™)
- •* Any other AHA with the exception of the protocol-approved agents
- •5. Meets the following criteria:
- •* Subject is on weight loss program and is not weight-stable.
- •* Subject is on a weight-loss medication (e.g., orlistat, phentermine/topiramate,
- •lorcaserin) and is not weight-stable.
- •* Subject is on other medications associated with weight changes (e.g., antipsychotic agents) and is not weight-stable.
- •* Subject has undergone bariatric surgery >12 months prior to Visit 1/Screening
- •and is not weight-stable.
- •* Subject has undergone bariatric surgery within 12 months of Visit
- •1/Screening.
- •Note: Weight-stable is defined as <5% change in body weight in the last 6 months.
- •Concomitant Disease of Organs and Systems
- •6. Has a history of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or NYHA functional class III-IV heart failure within 3 months of Visit 1/Screening.
- •7. Has active, obstructive uropathy or indwelling urinary catheter
- •8. Has a history of malignancy =5 years prior to signing the ICF, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer:
- •*Note (1) A subject with a history of malignancy =5 years prior to signing informed consent should have no evidence of residual or recurrent disease.
- •*Note (2) A subject with a history of melanoma, leukemia, lymphoma, or renal
- •carcinoma is excluded.
- •9. Has human immunodeficiency virus (HIV) as assessed by medical history.
- •* A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells,
- •* A clinically important hematological disorder (such as aplastic anemia,
- •myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
- •11. Has a medical history of active liver disease (other than non-alcoholic hepatic
- •steatosis), including chronic active hepatitis B or C (assessed by medical history),
- •primary biliary cirrhosis, or symptomatic gallbladder disease.
- •12. Has any clinically significant malabsorption condition.
- •13. Is currently being treated for hyperthyroidism
- •14. Is on thyroid replacement therapy and has not been on a stable dose for at least 6 weeks prior to Visit 1/Screening.
研究者
相似试验
暂停
3 期
A study of cefepime-tazobactam (FEP-TAZ) in complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)CTRI/2019/01/016861Wockhardt Bio AG501
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of Cefepime-Tazobactam in comparison to meropenem in hospitalized patients with complicated urinary tract infections or acute pyelonephritisEUCTR2017-005117-31-PLWockhardt Bio AG1,004
进行中（未招募）
1 期
A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe and effective when compared to ertugliflozin alone and Sitagliptin alone in patients with Type 2 Diabetes whose sugar levels are not well controlled by their current treatment with Metaformin.EUCTR2013-003698-82-BGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,250
进行中（未招募）
1 期
A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe and effective when compared to ertugliflozin alone and Sitagliptin alone in patients with Type 2 Diabetes whose sugar levels are not well controlled by their current treatment with Metaformin.Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin.MedDRA version: 16.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861EUCTR2013-003698-82-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,250
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of Cefepime-Tazobactam in comparison to meropenem in hospitalized patients with complicated urinary tract infections or acute pyelonephritisEUCTR2017-005117-31-LTWockhardt Bio AG1,004